Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cis-n-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide
2. Emonapride
3. Nemonapride, (cis)-isomer
4. Ym 09151-2
5. Ym 09151-m
6. Ym-09151-2
1. Emonapride
2. Emilace
3. [3h]nemonapride
4. 75272-39-8
5. (+)-nemonapride
6. (2r,3r)-nemonapride
7. N-[(2r,3r)-1-benzyl-2-methylpyrrolidin-3-yl]-5-chloro-2-methoxy-4-(methylamino)benzamide
8. Chebi:64219
9. Q88t5p3444
10. N-(cis-1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide
11. 187139-87-3
12. Nemonapride [inn:jan]
13. Ym-09151
14. Unii-q88t5p3444
15. Emilace (tn)
16. Ym-09151-2
17. Nemonapride (jan/inn)
18. Nemonapride [mi]
19. Nemonapride [inn]
20. Nemonapride [jan]
21. (+-)-cis-n-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-4-(methylamino)-o-anisamide
22. (+-)-cis-n-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide
23. N-(2rs,3rs)-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide
24. Nemonapride [mart.]
25. Gtpl962
26. Nemonapride [who-dd]
27. Schembl1649724
28. Chembl2261102
29. Dtxsid601116422
30. Zinc538069
31. Bdbm50487259
32. Pdsp1_001527
33. Pdsp2_001511
34. Ncgc00371107-01
35. Benzamide, 5-chloro-2-methoxy-4-(methylamino)-n-((2r,3r)-2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)-, Rel-
36. Benzamide, 5-chloro-2-methoxy-4-(methylamino)-n-(2-methyl-1-(phenylmethyl)-3-pyrrolidinyl)-, Cis-(+-)-
37. Hy-103415
38. B6843
39. Cs-0027847
40. D01468
41. Brd-k47289124-001-02-6
42. (+/-)-cis-n-(1-benzyl-2-methyl-3-pyrrolidinyl)-5-chloro-4-(methylamino)-o-anisamide
43. 5-chloro-2-methoxy-4-(methylamino)-n-[(2r,3r)-2-methyl-1-(phenylmethyl)-3-pyrrolidinyl]benzamide
44. 5-chloro-2-methoxy-4-methylamino-n-[(2r,3r)-2-methyl-1-(phenylmethyl)pyrrolidin-3-yl]benzamide
45. Benzamide, 5-chloro-2-methoxy-4-(methylamino)-n-(2-methyl-1- (phenylmethyl)-3-pyrrolidinyl)-, Cis-(+/-)-
| Molecular Weight | 387.9 g/mol |
|---|---|
| Molecular Formula | C21H26ClN3O2 |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Exact Mass | 387.1713548 g/mol |
| Monoisotopic Mass | 387.1713548 g/mol |
| Topological Polar Surface Area | 53.6 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 486 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
ABOUT THIS PAGE
A Nemonapride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nemonapride, including repackagers and relabelers. The FDA regulates Nemonapride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nemonapride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Nemonapride supplier is an individual or a company that provides Nemonapride active pharmaceutical ingredient (API) or Nemonapride finished formulations upon request. The Nemonapride suppliers may include Nemonapride API manufacturers, exporters, distributors and traders.
click here to find a list of Nemonapride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Nemonapride Drug Master File in Japan (Nemonapride JDMF) empowers Nemonapride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Nemonapride JDMF during the approval evaluation for pharmaceutical products. At the time of Nemonapride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Nemonapride suppliers with JDMF on PharmaCompass.
Nemonapride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nemonapride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nemonapride GMP manufacturer or Nemonapride GMP API supplier for your needs.
A Nemonapride CoA (Certificate of Analysis) is a formal document that attests to Nemonapride's compliance with Nemonapride specifications and serves as a tool for batch-level quality control.
Nemonapride CoA mostly includes findings from lab analyses of a specific batch. For each Nemonapride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nemonapride may be tested according to a variety of international standards, such as European Pharmacopoeia (Nemonapride EP), Nemonapride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nemonapride USP).
LOOKING FOR A SUPPLIER?
